Patients with type 2 diabetes, hypertension benefit from amlodipine/olmesartan medoxomil regimen
TUESDAY, April 26 (HealthDay News) -- An amlodipine/olmesartan medoxomil (OM)-based titration regimen is well tolerated and may reduce blood pressure (BP) in patients with hypertension and type 2 diabetes, according to a study published in the May 1 issue of The American Journal of Cardiology.
C. Venkata Ram, M.D., from the University of Texas Southwestern Medical School in Dallas, and colleagues assessed safety and efficacy of an amlodipine/OM-based titration regimen in 207 patients with type 2 diabetes mellitus and hypertension. Patients were given 5 mg amlodipine and were uptitrated in a stepwise manner at three-week intervals to amlodipine/OM 5/20, 5/40, and 10/40 mg and then amlodipine/OM 10/40 mg plus hydrochlorothiazide 12.5 and 25 mg, if the seated BP remained stable at ≥120/70 mm Hg. The primary end point measured was change in 24-hour ambulatory BP from baseline.
The investigators found a significant change in ambulatory BP at 12 weeks; the change from baseline in the mean ± standard error of the mean ambulatory systolic/diastolic BP was −19.9±0.8/−11.2±0.5 mm Hg. At the end of 18 weeks of active treatment in patients uptitrated to amlodipine/OM 10/40 mg plus hydrochlorothiazide 25 mg, the change was −28.0±1.5/−13.7±1.0 mm Hg. A guideline-recommended seated BP goal of less than 130/80 mm Hg was attained by 62 percent of patients. Drug-related adverse effects, such as peripheral edema, dizziness, and hypotension, were seen in 19.3 percent of patients.
"Amlodipine/OM-based titration regimen was well tolerated and effectively lowered BP throughout the 24-hour dosing interval in patients with hypertension and type 2 diabetes," the authors write.
Several of the study authors disclosed financial ties with the pharmaceutical industry, including Daiichi Sankyo Inc., which supported the study.
Full Text (subscription or payment may be required)